Premium
Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat
Author(s) -
CHARALAMBOUS DORA,
SKINNER STEWART A,
O'BRIEN PAUL E
Publication year - 1998
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1046/j.1440-1746.1998.01779.x
Subject(s) - sulindac , medicine , prostaglandin , prostaglandin e2 , prostaglandin antagonist , endocrinology , prostaglandin e , growth inhibition , pharmacology , cell growth , nonsteroidal , biology , biochemistry
We have determined the dose‐response relationship between sulindac administration and inhibition of tumour growth in the rat. The effect of tumour‐inhibiting doses of sulindac on the production of prostaglandin E in tumours and macroscopically normal colon was then examined. Growth of pre‐existing tumours was significantly reduced following administration of sulindac at 0.1 ( P = 0.004), 1 ( P = 0.01), 3 ( P < 0.001) and 10mg/kg b.d. ( P = 0.002) for 4 weeks. There was no significant difference in prostaglandin E synthesis between tumours from control rats and those treated with sulindac at either 3 or 10mg/kg b.d. ( P = 0.09 and 0.4, respectively). Prostaglandin E synthesis was reduced by 33 and 32% in macroscopically normal tissue from these treatment groups. These data show that sulindac inhibits tumour growth at low doses and do not support a role for the inhibition of prostaglandin synthesis, by sulindac, in the inhibition of tumour growth.